Results suggested that ORI can synergistically improve the antitumor effect of CIS, with p53 mutation and glutathione deficiency as biomarkers for the use of ORI and CIS in combination (Yang et al., 2022). The gene discussed is TP53; the disease is in situ carcinoma.